U.S. markets closed

BAYER (BAY.TI)

TLO - TLO Delayed Price. Currency in EUR
Add to watchlist
53.60+0.29 (+0.54%)
At close: 3:17PM CEST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close53.31
Open53.32
Bid53.56 x 40000
Ask53.61 x 40000
Day's Range53.32 - 53.32
52 Week Range53.32 - 53.32
Volume100
Avg. VolumeN/A
Market CapN/A
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Bayer's Cell, Gene Therapies for Parkinson's Disease Enters Human Trials
      Benzinga

      Bayer's Cell, Gene Therapies for Parkinson's Disease Enters Human Trials

      Bayer AG’s (OTC: BAYRY) Parkinson’s disease stem cell therapy has officially landed in the clinic, while another treatment for the neurodegenerative movement disorder is recruiting patients. Bayer’s subsidiary BlueRock Therapeutics’s trial will eventually enroll 10 participants. Patients will have dopamine-producing cells surgically implanted into a part of the brain called the putamen. The trial will primarily examine the safety and tolerability of DA01 cell transplantation a year after the pro

    • Novartis (NVS) Posts Positive Data on Kidney Disease Candidate
      Zacks

      Novartis (NVS) Posts Positive Data on Kidney Disease Candidate

      Novartis' (NVS) rare kidney disease candidate meets its primary goal in a phase II study.

    • Bayer Buys Two Biotech Firms to Beef Up Radiopharmaceuticals
      Benzinga

      Bayer Buys Two Biotech Firms to Beef Up Radiopharmaceuticals

      Bayer AG (OTC: BAYRY) will acquire two small biotech companies in a deal that adds an experimental prostate cancer medicine to the German drugmaker's pipeline. Bayer will pay an undisclosed sum for Noria Therapeutics and PSMA Therapeutics, built around radiotherapy research from the Weill Cornell Medical College in NYC. The deal is centered around an actinium-225 labeled prostate-specific membrane antigen (PSMA) small molecule currently in pre-IND studies for prostate cancer. Bayer has its portf